First-of-its-kind Parkinson’s trial, Brexit woes, and a vaccine scandal in China… What’s new for pharma in business?
James Strachan |
- The FDA’s Center for Biologics Evaluation and Research (CBER) unveiled six new draft guidance documents covering gene therapy. The guidance documents focus on i) rare disease therapies, ii) retinal disorder therapies, iii) haemophilia therapies, iv) chemistry, manufacturing and control (CMC) information, v) long-term follow-up observational studies that collect data on adverse events, and vi) retroviral vector-based therapies testing.
- Japanese scientists will use induced pluripotent stem (iPS) cells in a Parkinson’s trial for the first time, following successful animal studies. In an attempt to replace the lost dopaminergic cells responsible for Parkinson’s, the researchers, led by Jun Takahashi at Kyoto University’s Center for iPS Cell Research and Application (CiRA), will derive dopaminergic progenitors from iPS cells and inject roughly five million of them into the forebrain. Sumitomo Dainippon Pharma hopes to manufacture and start selling cellular medicine based on the data from the clinical trials by March 2023.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.